Citations

Clear

1446 citation(s) found for "Howard, F".

[O2‐02‐06]: Using family history to enrich recruitment in prevention trials: Does relative's age matter?
Sano, Mary , Bell, Karen L. , Andrews, Howard , Tsai, Wei‐Yann , Lucas, John A. , Graff‐Radford, Neill R. , Bolla, Karen I., Rabins, Peter V., Jacobs, Diane M.

Mayo Clinic

Alzheimer's & Dementia | August 25, 2005 | Volume: 1 | Issue: 1S_Part_3 | Pages: No page available

10.1016/j.jalz.2005.06.339 Get It

Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
Geyer, Susan M. , Inwards, David J. , Fonseca, Rafaël , Kurtin, Paul J. , Ansell, Stephen M. , Luyun, Ronnie F., Flynn, Patrick J. , Morton, Roscoe F., Dakhil, Shaker R. , Gross, Howard M., Witzig, Thomas E. , Ghobrial, Irene M. , Kaufmann, Scott H. , Fonseca, Rafael

Mayo Clinic

Journal of Clinical Oncology | June 28, 2005 | Volume: 23 | Issue: 23 | Pages: 5347-5356

10.1200/jco.2005.13.466 | PMID 15983389 Get It

PurposeMantle cell lymphoma (MCL) is characterized by a t(11;14) resulting in overexpression of cyclin D1 messenger RNA. This study tested whether temsirolimus (previously known as CCI-779), an inhibitor of the mammalian target of rapamycin kinase that regulates cyclin D1 translation, could produce tumor responses in patients with MCL.Patients and MethodsPatients with relapsed or refractory MCL were eligible to receive temsirolimus 250 mg intravenously every week as a single agent. Patients with a tumor response after six cycles were eligible to continue drug for a total of 12 cycles or two cycles after complete remission, and were then observed without maintenance.ResultsThirty-five patients were enrolled and were assessable for toxicity; one patient had MCL by histology but was cyclin D1 negative and was ineligible for efficacy. The median age was 70 years (range, 38 to 89 years), 91% were stage 4, and 69% had two or more extranodal sites. Patients had received a median of three prior therapies (range, one to 11), and 54% were refractory to the last treatment. The overall response rate was 38% (13 of 34 patients; 90% CI, 24% to 54%) with one complete response (3%) and 12 partial responses (35%). The median time-to-progression in all patients was 6.5 months (95% CI, 2.9 to 8.3 months), and the duration of response for the 13 responders was 6.9 months (95% CI, 5.2 to 12.4 months). Hematologic toxicities were the most common, with 71% (25 of 35 patients) having grade 3 and 11% (four of 35 patients) having grade 4 toxicities observed. Thrombocytopenia was the most frequent cause of dose reductions but was of short duration, typically resolving within 1 week.ConclusionsSingle-agent temsirolimus has substantial antitumor activity in relapsed MCL. This study demonstrates that agents that selectively target cellular pathways dysregulated in MCL cells can produce therapeutic benefit. Further studies of this agent in MCL and other lymphoid malignancies are warranted.
Use of Internal Reflectance Infrared Spectroscopy for the in Situ Study of Supported Lipid Monolayers
Axelsen, Paul H. , Braddock, W. David, Brockman, Howard L., Jones, C.M., Dluhy, Richard A. , Kaufman, Brad K., Puga, Francisco J.

Mayo Clinic

Applied Spectroscopy | May 21, 2005 | Volume: 49 | Issue: 4 | Pages: 526-531

10.1366/0003702953964273 Get It

An instrument has been developed to acquire polarized attenuated total internal reflection (ATIR) mid-IR spectra of supported monomolecular films in situ at the lipid/water (L/W) interface. The monolayer film is applied to the treated surface of a trapezoidal germanium crystal as it is immersed into the subphase of a specially designed Langmuir-Blodgett trough. This approach offers several advantages over the study of monolayer films at the air/water (A/W) interface by external reflection techniques, including (1) an improved signal throughput and multiple reflections, both contributing to an improved signal-to-noise (S/N) ratio; (2) versatility with respect to the chemical nature of the surface; and (3) the ability to use standard spectral subtraction methods to compensate for absorption of the aqueous subphase. The enhanced sensitivity of this approach facilitates the study of in situ interactions of peptides with fully hydrated lipid membrane surfaces.
Increasing Access to Clinical Cancer Trials and Emerging Technologies for Minority Populations: The Native American Project
Petereit, Daniel G. , Rogers, Deborah, Govern, Frank S., Coleman, Norman, Osburn, Christen H., Howard, Steve , Kaur, Judith S. , Burhansstipanov, Linda , Fowler, C. Jack F., Mehta, Minesh P. , Chappell, Richard J. , Mehta, Minesh P

Mayo Clinic

Journal of Clinical Oncology | November 12, 2004 | Volume: 22 | Issue: 22 | Pages: 4452-4455

10.1200/jco.2004.01.119 | PMID 15542797 Get It

53BP1 is required for class switch recombination
Ward, Irene M., Reina‐San‐Martin, Bernardo , Olaru, Alexandru, Minn, Kay, Tamada, Koji , Lau, Julie S., Cascalho, Marília , Nussenzweig, André , Livák, Ferenc , Nussenzweig, Michel C. , Nussenzweig, André , Chen, Lieping , Chen, Junjie

Mayo Clinic

The Journal of Cell Biology | May 24, 2004 | Volume: 165 | Issue: 4 | Pages: 459-464

10.1083/jcb.200403021 | PMID 15159415 Get It

53BP1 participates early in the DNA damage response and is involved in cell cycle checkpoint control. Moreover, the phenotype of mice and cells deficient in 53BP1 suggests a defect in DNA repair (Ward et al., 2003b). Therefore, we asked whether or not 53BP1 would be required for the efficient repair of DNA double strand breaks. Our data indicate that homologous recombination by gene conversion does not depend on 53BP1. Moreover, 53BP1-deficient mice support normal V(D)J recombination, indicating that 53BP1 is not required for “classic” nonhomologous end joining. However, class switch recombination is severely impaired in the absence of 53BP1, suggesting that 53BP1 facilitates DNA end joining in a way that is not required or redundant for the efficient closing of RAG-induced strand breaks. These findings are similar to those observed in mice or cells deficient in the tumor suppressors ATM and H2AX, further suggesting that the functions of ATM, H2AX, and 53BP1 are closely linked.
The Caregivers’ Story: Home Caregiving for Persons with Dementia
Kelly, Ann W., Buckwalter, Kathleen C., Hall, Geri Richards, Weaver, Amy L. , Butcher, Howard K.

Mayo Clinic

Home Health Care Management & Practice | April 28, 2003 | Volume: 14 | Issue: 2 | Pages: 99-109

10.1177/1084822302014002004 Get It

This study identified the salient issues of caregiving for family members of persons with dementia using computer-assisted content analysis followed by factor analysis. Differences in responses between caregivers in two treatment groups were also noted. Caregivers (N = 226) were interviewed on three occasions over 12 months. They consistently identified the following themes of caregiving in order of significance: (a) making meaning of the experience; (b) defining the caregiver role; (c) identifying specific caregiving strategies; (d) dealing with change, unpredictability, and vulnerability; (e) evaluating past and future decisions and quality of care; and (f) finding help and support. This representation of the caregiving experience is useful to home care nurses by providing a framework to address issues most important to caregivers and upon which therapeutic interventions can be developed.
Modeling and Risk Prediction in the Current Era of Interventional Cardiology
Holmes, David R. , Selzer, Faith , Kelsey, Sheryl F., Holubkov, Richard , Cohen, Howard, Williams, David O., Detre, Katherine M., Johnston, Janet M. , Holubkov, Richard

Mayo Clinic

Circulation | April 14, 2003 | Volume: 107 | Issue: 14 | Pages: 1871-1876

10.1161/01.cir.0000065229.72905.78 | PMID 12668511 Get It

Background— Validation of in-hospital mortality models after percutaneous coronary interventions using multicenter data remains limited. Methods and Results— This study evaluated whether multivariable mortality models developed during the pre-stent era by New York State, American College of Cardiology (ACC)–National Cardiovascular Data Registry, Northern New England Cooperative Group, Cleveland Clinic Foundation, and the University of Michigan are relevant in patients undergoing percutaneous coronary intervention in the 1997 to 1999 National Heart, Lung, and Blood Institute Dynamic Registry. Of 4448 Dynamic Registry patients, 73% received ≥1 stent and 28% received a IIB/IIIA receptor inhibitor. In-hospital mortality occurred in 64 patients (1.4%). The New York state model predicted mortality in 69 patients (1.5%; 95% confidence bounds [CI], 0.89% to 1.70%); Northern New England predicted mortality in 60 patients (1.3%; 95% CI, 1.0% to 1.7%); and Cleveland Clinic predicted mortality in 76 patients (1.7%; 95% CI, 1.3% to 2.1%). Among high-risk subgroups, with these 3 models, observed and predicted in-hospital mortality rates in general were not different. The other 2 models yielded different results. The University of Michigan predicted fewer deaths (n=47; 1.1%; 95% CI, 0.7% to 1.3%), and the ACC Registry model predicted 603 deaths (13.5%; 95% CI, 12.6% to 14.4%). Using the ACC Registry model, predicted mortality was higher than observed in each subgroup. Conclusions— Application of 5 mortality risk models developed from different data sets to patients undergoing percutaneous coronary intervention in the Dynamic Registry predicted, in 3 models, mortality rates that were not significantly different than those observed. In both high and low risk subgroups, the University of Michigan slightly underpredicted mortality, and the ACC Registry predicted significantly higher mortality than that observed.
Bro1 is an endosome-associated protein that functions in the MVB pathway in Saccharomyces cerevisiae
Odorizzi, Greg , Katzmann, David J. , Babst, Markus , Emr, Scott D. , Audhya, Anjon

Mayo Clinic

Journal of Cell Science | April 11, 2003 | Volume: 116 | Issue: 10 | Pages: 1893-1903

10.1242/jcs.00395 | PMID 12668726 Get It

Multivesicular bodies are late endosomal compartments containing lumenal vesicles that are formed by inward budding of the limiting endosomal membrane. In the yeast Saccharomyces cerevisiae, integral membrane proteins are sorted into the lumenal vesicles of multivesicular bodies, and this process requires the class E subset of VPS genes. We show that one of the class E VPS genes, BRO1/VPS31, encodes a cytoplasmic protein that associates with endosomal compartments. The dissociation of Bro1 from endosomes requires another class E Vps protein, Vps4, which is an ATPase that also regulates the endosomal dissociation of ESCRT-III, a complex of four class E Vps proteins (Vps2, Vps20, Vps24 and Snf7/Vps32) that oligomerize at the endosomal membrane. We also show that the endosomal association of Bro1 is specifically dependent on one of the ESCRT-III components, Snf7. Our data suggest that the function of Bro1 in the MVB pathway takes place on endosomal membranes and occurs in concert with or downstream of the function of the ESCRT-III complex.
Future Research Directions in Acute Lung Injury: Summary of a National Heart, Lung, and Blood Institute Working Group
Matthay, Michael A. , Esmon, Charles, Bhattacharya, Jahar , Floros, Joanna, Gimbrone, Michael A., Hubmayr, Rolf D., Matalon, Sadis , Munford, Robert S., Parsons, Polly E., Slutsky, Arthur S. , Tracey, Kevin J. , Ward, Peter A. , Gail, Dorothy B., Harabin, Andrea L., Zimmerman, Guy A. , Esmon, Charles T., Coller, Barry S. , Doerschuk, Claire M. , Hoffman, Eric P. , Leppert, Mark

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | March 27, 2003 | Volume: 167 | Issue: 7 | Pages: 1027-1035

10.1164/rccm.200208-966ws | PMID 12663342 Get It

Abstract Acute lung injury (ALI) and its more severe form, the acute respiratory distress syndrome (ARDS), are syndromes of acute respiratory failure that result from acute pulmonary edema and inflammation. The development of ALI/ARDS is associated with several clinical disorders including direct pulmonary injury from pneumonia and aspiration as well as indirect pulmonary injury from trauma, sepsis, and other disorders such as acute pancreatitis and drug overdose. Although mortality from ALI/ARDS has decreased in the last decade, it remains high. Despite two major advances in treatment, low VT ventilation for ALI/ARDS and activated protein C for severe sepsis (the leading cause of ALI/ARDS), additional research is needed to develop specific treatments and improve understanding of the pathogenesis of these syndromes. The NHLBI convened a working group to develop specific recommendations for future ALI/ARDS research. Improved understanding of disease heterogeneity through use of evolving biologic, genomic, and genetic approaches should provide major new insights into pathogenesis of ALI. Cellular and molecular methods combined with animal and clinical studies should lead to further progress in the detection and treatment of this complex disease.
Intestinal mucins from cystic fibrosis mice show increased fucosylation due to an induced Fucα1-2 glycosyltransferase
Thomsson, Kristina A. , Hinojosa-Kurtzberg, Marina, Axelsson, Karin , Domino, Steven E. , Gendler, Sandra , Hansson, Gunnar C. , Lowe, John B.

Mayo Clinic

Biochemical Journal | October 25, 2002 | Volume: 367 | Issue: 3 | Pages: 609-616

10.1042/bj20020371 | PMID 12164788 Get It

In gene-targeted mouse models for cystic fibrosis (CF), the disease is mainly manifested by mucus obstruction in the intestine. To explore the mucus composition, mucins insoluble and soluble in 6M guanidinium chloride were purified by three rounds of isopycnic ultracentrifugation from the small and large intestines of CF mice (Cftrm1UNC/Cftrm1UNC) and compared with wild-type mice. The amino acid composition was typical of that for mucins and showed increased amounts of the insoluble (2.5-fold increase) and soluble (7-fold increase) mucins in the small intestine of the CF mice compared with wild-type mice. Mucins from the large intestine of both wild-type and CF mice showed a high but constant level of fucosylation. In contrast, the insoluble and soluble mucins of the small intestine in CF mice revealed a large increase in fucose, whereas those of wild-type mice contained only small amounts of fucose. This increased fucosylation was analysed by releasing the O-linked oligosaccharides followed by GC-MS. NMR spectroscopy revealed that the increased fucosylation was due to an increased expression of blood group H epitopes (Fucα1-2Gal-). Northern-blot analysis, using a probe for the murine Fucα1-2 fucosyltransferase (Fut2), showed an up-regulation of this mRNA in the small intestine of the CF mice, suggesting that this enzyme is responsible for the observed increase in blood group H-type glycosylation. The reason for this up-regulation could be a direct or indirect effect of a non-functional CF transmembrane conductance regulator (CFTR) caused by the absence of CFTR channel.